Falla A M, Ahmad A A, Duffell E, Noori T, Veldhuijzen I K
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Division of Infectious Disease Control, Municipal Public Health Service Rotterdam-Rijnmond, PO Box 70032, 3000, LP, Rotterdam, The Netherlands.
BMC Infect Dis. 2018 Jan 16;18(1):42. doi: 10.1186/s12879-017-2908-5.
Increasing the proportion diagnosed with and on treatment for chronic hepatitis C (CHC) is key to the elimination of hepatitis C in Europe. This study contributes to secondary prevention planning in the European Union/European Economic Area (EU/EEA) by estimating the number of CHC (anti-HCV positive and viraemic) cases among migrants living in the EU/EEA and born in endemic countries, defining the most affected migrant populations, and assessing whether country of birth prevalence is a reliable proxy for migrant prevalence.
Migrant country of birth and population size extracted from statistical databases and anti-HCV prevalence in countries of birth and in EU/EEA countries derived from a systematic literature search were used to estimate caseload among and most affected migrants. Reliability of country of birth prevalence as a proxy for migrant prevalence was assessed via a systematic literature search.
Approximately 11% of the EU/EEA adult population is foreign-born, 79% of whom were born in endemic (anti-HCV prevalence ≥1%) countries. Anti-HCV/CHC prevalence in migrants from endemic countries residing in the EU/EEA is estimated at 2.3%/1.6%, corresponding to ~580,000 CHC infections or 14% of the CHC disease burden in the EU/EEA. The highest number of cases is found among migrants from Romania and Russia (50-60,000 cases each) and migrants from Italy, Morocco, Pakistan, Poland and Ukraine (25-35,000 cases each). Ten studies reporting prevalence in migrants in Europe were identified; in seven of these estimates, prevalence was comparable with the country of birth prevalence and in three estimates it was lower.
Migrants are disproportionately affected by CHC, account for a considerable number of CHC infections in EU/EEA countries, and are an important population for targeted case finding and treatment. Limited data suggest that country of birth prevalence can be used as a proxy for the prevalence in migrants.
提高慢性丙型肝炎(CHC)的诊断率和治疗率是欧洲消除丙型肝炎的关键。本研究通过估计居住在欧盟/欧洲经济区(EU/EEA)且出生于流行国家的移民中CHC(抗-HCV阳性且病毒血症)病例的数量、确定受影响最大的移民群体以及评估出生国患病率是否可作为移民患病率的可靠替代指标,为欧盟/欧洲经济区的二级预防规划做出贡献。
从统计数据库中提取移民的出生国和人口规模,并通过系统文献检索得出出生国以及欧盟/欧洲经济区国家的抗-HCV患病率,以此来估计受影响最大的移民群体中的病例数。通过系统文献检索评估出生国患病率作为移民患病率替代指标的可靠性。
欧盟/欧洲经济区约11%的成年人口为外国出生,其中79%出生于流行国家(抗-HCV患病率≥1%)。居住在欧盟/欧洲经济区的来自流行国家的移民中,抗-HCV/CHC患病率估计为2.3%/1.6%,相当于欧盟/欧洲经济区约58万例CHC感染病例,占CHC疾病负担的14%。病例数最多的是来自罗马尼亚和俄罗斯的移民(各5万 - 6万例)以及来自意大利、摩洛哥、巴基斯坦、波兰和乌克兰的移民(各2.5万 - 3.5万例)。共确定了10项报告欧洲移民患病率的研究;其中7项估计的患病率与出生国患病率相当,3项估计的患病率较低。
移民受CHC影响的比例过高,在欧盟/欧洲经济区国家的CHC感染病例中占相当数量,是目标病例发现和治疗的重要人群。有限的数据表明,出生国患病率可作为移民患病率的替代指标。